Plasmin-dependent modulation of the blood-brain barrier: A major consideration during tPA-induced thrombolysis?

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 8, 2014, Pages 1283-1296

  Niego, Be'Eri ^a   Medcalf, Robert L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

blood brain barrier; intracerebral hemorrhage; plasmin; stroke; thrombolysis; tPA

Indexed keywords

ALTEPLASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMIN; PLASMINOGEN; RHO KINASE; TISSUE PLASMINOGEN ACTIVATOR;

ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN CELL; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; RECOMBINANT PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84905513820     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.99     Document Type: Review

References (153)

1. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-630.
2. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-321.
3. Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004; 2: 541-546.
4. NINDS trial. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
6. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 2008; 79: 1093-1099.
7. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
8. Sappino AP, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92: 679-685.
9. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
10. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17: 543-552.
11. Soreq H, Miskin R. Plasminogen activator in the rodent brain. Brain Res 1981; 216: 361-374.
12. Salles FJ, Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 2002; 22: 2125-2134.
13. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for bloodbrain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376-385.
14. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93: 655-660.
15. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50: 673-678.
16. Vivien D, Gauberti M, Montagne A, Defer G, Touze E. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab 2011; 31: 2119-2134.
17. NINDS Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109-2118.
18. Hill MD, Barber PA, Demchuk AM, Sevick RJ, Frayne R, Buchan AM. Symptomatic hemorrhage after alteplase therapy not due to silent ischemia. BMC Neurol 2001; 1: 1.
19. Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. Stroke 1998; 29: 563-569.
20. Jaffer H, Adjei IM, Labhasetwar V. Optical imaging to map blood-brain barrier leakage. Sci Rep 2013; 3: 3117.
21. Abu Fanne R, Nassar T, Yarovoi S, Rayan A, Lamensdorf I, Karakoveski M et al. Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 2010; 58: 972-980.
22. Turner RJ, Vink R. Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats. Neuroscience 2012; 220: 1-10.
23. Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez-Atalaya JP, Brillault J et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005; 111: 2241-2249.
24. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-737.
25. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-1285.
26. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissuetype plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-1540.
27. Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 2007; 109: 3270-3278.
28. Kassner A, Roberts TP, Moran B, Silver FL, Mikulis DJ. Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an MR imaging permeability study. AJNR Am J Neuroradiol 2009; 30: 1864-1869.
29. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008; 25: 338-343.
30. del Zoppo GJ, Izawa Y, Hawkins BT. Hemostasis and alterations of the central nervous system. Semin Thromb Hemost 2013; 39: 856-875.
31. del Zoppo GJ, Copeland BR, Anderchek K, Hacke W, Koziol JA. Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke 1990; 21: 596-601.
32. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31: 3034-3040.
33. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002; 106: 740-745.
34. Won S, Lee JH, Wali B, Stein DG, Sayeed I. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway. J Cereb Blood Flow Metab 2014; 34: 72-80.
35. Ishiguro M, Kawasaki K, Suzuki Y, Ishizuka F, Mishiro K, Egashira Y et al. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9- related hemorrhagic transformation in mice treated with tissue plasminogen activator. Neuroscience 2012; 220: 302-312.
36. Ishiguro M, Mishiro K, Fujiwara Y, Chen H, Izuta H, Tsuruma K et al. Phosphodiesterase- III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010; 5: e15178.
37. Yagi K, Kitazato KT, Uno M, Tada Y, Kinouchi T, Shimada K et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009; 40: 626-631.
38. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009; 29: 715-725.
39. Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Lijnen HR, Umemura K. Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood 2009; 114: 3352-3358.
40. Teng F, Beray-Berthat V, Coqueran B, Lesbats C, Kuntz M, Palmier B et al. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice. Exp Neurol 2013; 248: 416-428.
41. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 5: 1732-1739.
42. Lukic-Panin V, Deguchi K, Yamashita T, Shang J, Zhang X, Tian F et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res 2010; 7: 319-329.
43. Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human BBB model involves plasmin-mediated activation of the Rho-kinase pathway in astrocytes. Blood 2012; 119: 4752-4761.
44. Armstead WM, Nassar T, Akkawi S, Smith DH, Chen XH, Cines DB et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 2006; 9: 1150-1155.
45. Rickles RJ, Darrow AL, Strickland S. Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation. J Biol Chem 1988; 263: 1563-1569.
46. Lijnen HR, van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224: 863-871.
47. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981; 46: 561-565.
48. Acheampong P, Ford GA. Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol 2012; 8: 271-281.
49. Samson AL, Nevin ST, Medcalf RL. Low molecular weight contaminants in commercial preparations of plasmin and t-PA activate neurons. J Thromb Haemost 2008; 6: 2218-2220.
50. Roussel BD, Macrez R, Jullienne A, Agin V, Maubert E, Dauphinot L et al. Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain 2009; 132: 2219-2230.
51. Hosomi N, Lucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 2001; 32: 1341-1348.
52. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP et al. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 1408-1419.
53. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemiainduced apoptosis. Blood 2000; 96: 569-576.
54. Sashindranath M, Samson AL, Downes CE, Crack PJ, Lawrence AJ, Li QX et al. Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation. Lab Invest 2011; 91: 1079-1091.
55. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4: 228-231.
56. Sashindranath M, Sales E, Daglas M, Freeman R, Samson AL, Cops EJ et al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 2012; 135: 3251-3264.
57. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007; 22: E4.
58. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007; 6: 258-268.
59. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165-2170.
60. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005; 36: 1954-1959.
61. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysisassociated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-836.
62. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptormediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313-1317.
63. Zhang C, An J, Haile WB, Echeverry R, Strickland DK, Yepes M. Microglial lowdensity lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the ischemic brain. J Cereb Blood Flow Metab 2009; 29: 1946-1954.
64. Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X et al. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 2006; 37: 1910-1912.
65. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004; 103: 897-902.
66. Akkawi S, Nassar T, Tarshis M, Cines DB, Higazi AA. LRP and avb3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 291: H1351-H1359.
67. Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, Milev P et al. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizureinduced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 2000; 148: 1295-1304.
68. Nakagami Y, Abe K, Nishiyama N, Matsuki N. Laminin degradation by plasmin regulates long-term potentiation. J Neurosci 2000; 20: 2003-2010.
69. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-925.
70. Min KJ, Jou I, Joe E. Plasminogen-induced IL-1beta and TNF-alpha production in microglia is regulated by reactive oxygen species. Biochem Biophys Res Commun 2003; 312: 969-974.
71. Fujimoto S, Katsuki H, Ohnishi M, Takagi M, Kume T, Akaike A. Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2008; 28: 506-515.
72. Pfefferkorn T, Wiessner C, Allegrini PR, Staufer B, Vosko MR, Liebetrau M et al. Plasminogen activation in experimental permanent focal cerebral ischemia. Brain Res 2000; 882: 19-25.
73. Pfefferkorn T, Staufer B, Liebetrau M, Bultemeier G, Vosko MR, Zimmermann C et al. Plasminogen activation in focal cerebral ischemia and reperfusion. J Cereb Blood Flow Metab 2000; 20: 337-342.
74. Tagaya M, Haring HP, Stuiver I, Wagner S, Abumiya T, Lucero J et al. Rapid loss of microvascular integrin expression during focal brain ischemia reflects neuron injury. J Cereb Blood Flow Metab 2001; 21: 835-846.
75. Jin X, Liu J, Yang Y, Liu KJ, Yang Y, Liu W. Spatiotemporal evolution of blood brain barrier damage and tissue infarction within the first 3 h after ischemia onset. Neurobiol Dis 2012; 48: 309-316.
76. Albayrak S, Zhao Q, Siesjo BK, Smith ML. Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury. Acta Neuropathol 1997; 94: 158-163.
77. Chen ZL, Indyk JA, Bugge TH, Kombrinck KW, Degen JL, Strickland S. Neuronal death and blood-brain barrier breakdown after excitotoxic injury are independent processes. J Neurosci 1999; 19: 9813-9820.
78. Seifried E, Tanswell P, Ellbruck D, Haerer W, Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost 1989; 61: 497-501.
79. Stief TW, Richter A, Bunder R, Maisch B, Renz H. Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase. Clin Appl Thromb Hemost 2006; 12: 213-218.
80. Benchenane K, Berezowski V, Fernandez-Monreal M, Brillault J, Valable S, Dehouck MP et al. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRPindependent process. Stroke 2005; 36: 1065-1070.
81. Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci 2005; 10: 300-325.
82. Miles LA, Parmer RJ. Plasminogen receptors: the first quarter century. Semin Thromb Hemost 2013; 39: 329-337.
83. Samson AL, Borg RJ, Niego B, Wong CH, Crack PJ, Yongqing T et al. A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury. Blood 2009; 114: 1937-1946.
84. Samson AL, Knaupp AS, Sashindranath M, Borg RJ, Au AE, Cops EJ et al. Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin. Cell Rep 2012; 2: 889-901.
85. Basham ME, Seeds NW. Plasminogen expression in the neonatal and adult mouse brain. J Neurochem 2001; 77: 318-325.
86. Taniguchi Y, Inoue N, Morita S, Nikaido Y, Nakashima T, Nagai N et al. Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus. Cell Tissue Res 2011; 343: 303-317.
87. Zhang L, Seiffert D, Fowler BJ, Jenkins GR, Thinnes TC, Loskutoff DJ et al. Plasminogen has a broad extrahepatic distribution. Thromb Haemost 2002; 87: 493-501.
88. Xin H, Li Y, Shen LH, Liu X, Wang X, Zhang J et al. Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse. PLoS One 2010; 5: e9027.
89. Matsuoka Y, Kitamura Y, Taniguchi T. Induction of plasminogen in rat hippocampal pyramidal neurons by kainic acid. Neurosci Lett 1998; 252: 119-122.
90. Sharon R, Abramovitz R, Miskin R. Plasminogen mRNA induction in the mouse brain after kainate excitation: codistribution with plasminogen activator inhibitor- 2 (PAI-2) mRNA. Brain Res Mol Brain Res 2002; 104: 170-175.
91. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000; 2: 302-309.
92. Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2008; 49: 42-48.
93. Riehle KJ, Johnson MM, Johansson F, Bauer RL, Hayes BJ, Gilbertson DG et al. Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation. Biochim Biophys Acta 2014; 1842: 318-325.
94. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6001.
95. Marchina E, Barlati S. Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase. Int J Biochem Cell Biol 1996; 28: 1141-1150.
96. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase- 2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002; 192: 160-170.
97. Makowski GS, Ramsby ML. Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation 1998; 22: 287-305.
98. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/ stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
99. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997; 16: 2319-2332.
100. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998; 65: 1-9.
101. Chen ZL, Yao Y, Norris EH, Kruyer A, Jno-Charles O, Akhmerov A et al. Ablation of astrocytic laminin impairs vascular smooth muscle cell function and leads to hemorrhagic stroke. J Cell Biol 2013; 202: 381-395.
102. Suofu Y, Clark JF, Broderick JP, Kurosawa Y, Wagner KR, Lu A. Matrix metalloproteinase- 2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. Neuroscience 2012; 212: 180-189.
103. Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol 2012; 92: 509-519.
104. Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci 2011; 68: 785-801.
105. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 13333-13339.
106. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysinebinding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-154.
107. Choi BH, Suzuki M, Kim T, Wagner SL, Cunningham DD. Protease nexin-1. Localization in the human brain suggests a protective role against extravasated serine proteases. Am J Pathol 1990; 137: 741-747.
108. Coughlin PB. Antiplasmin: the forgotten serpin? FEBS J 2005; 272: 4852-4857.
109. Wang H, Pap S, Wiman B. Inactivation of antiplasmin at low pH: evidence for the formation of latent molecules. Thromb Res 2004; 114: 301-306.
110. Simon R, Xiong Z. Acidotoxicity in brain ischaemia. Biochem Soc Trans 2006; 34: 1356-1361.
111. Absher PM, Hendley E, Jaworski DM, Taatjes DJ, Sobel BE. Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs. Coron Artery Dis 1999; 10: 413-420.
112. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003; 101: 3002-3007.
113. Armao D, Kornfeld M, Estrada EY, Grossetete M, Rosenberg GA. Neutral proteases and disruption of the blood-brain barrier in rat. Brain Res 1997; 767: 259-264.
114. Xue M, Del Bigio MR. Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke 2001; 32: 2164-2169.
115. Marder VJ, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J Thromb Haemost 2010; 8: 433-444.
116. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-745.
117. Burggraf D, Vosko MR, Schubert M, Stassen JM, Hamann GF. Different therapy options protecting microvasculature after experimental cerebral ischaemia and reperfusion. Thromb Haemost 2010; 103: 891-900.
118. Suzuki Y, Nagai N, Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haemost 2004; 2: 1617-1621.
119. Nagy Z, Kolev K, Csonka E, Vastag M, Machovich R. Perturbation of the integrity of the blood-brain barrier by fibrinolytic enzymes. Blood Coagul Fibrinolysis 1998; 9: 471-478.
120. Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A et al. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 2003; 34: 2975-2979.
121. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99: 2440-2444.
122. Yao Y, Tsirka SE. Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J Cell Sci 2011; 124: 1486-1495.
123. Fujiyoshi T, Hirano K, Hirano M, Nishimura J, Takahashi S, Kanaide H. Plasmin induces endothelium-dependent nitric oxide-mediated relaxation in the porcine coronary artery. Arterioscler Thromb Vasc Biol 2007; 27: 949-954.
124. Weinstein JR, Gold SJ, Cunningham DD, Gall CM. Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. J Neurosci 1995; 15: 2906-2919.
125. Bartha K, Domotor E, Lanza F, Adam-Vizi V, Machovich R. Identification of thrombin receptors in rat brain capillary endothelial cells. J Cereb Blood Flow Metab 2000; 20: 175-182.
126. Doeuvre L, Plawinski L, Goux D, Vivien D, Angles-Cano E. Plasmin on adherent cells: from microvesiculation to apoptosis. Biochem J 2010; 432: 365-373.
127. Nagy Z, Kolev K, Csonka E, Pek M, Machovich R. Contraction of human brain endothelial cells induced by thrombogenic and fibrinolytic factors. An in vitro cell culture model. Stroke 1995; 26: 265-270.
128. Conforti G, Dominguez-Jimenez C, Ronne E, Hoyer-Hansen G, Dejana E. Cellsurface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer. Blood 1994; 83: 994-1005.
129. Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR et al. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci 2011; 31: 14346-14360.
130. Armstead WM, Kiessling JW, Riley J, Cines DB, Higazi AA. tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res 2011; 33: 726-733.
131. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987; 325: 253-257.
132. Dehouck B, Dehouck MP, Fruchart JC, Cecchelli R. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol 1994; 126: 465-473.
133. Liu Y, Honda S, Kohsaka S, Nakajima K. Plasminogen enhances the secretion of plasminogen activator inhibitor-1 from cultured rat astrocytes. Neurosci Lett 2000; 282: 137-140.
134. Gao Y-J, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu Z-Z et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009; 29: 4096-4108.
135. Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol 2005; 67: 2-11.
136. Adams MN, Ramachandran R, Yau M-K, Suen JY, Fairlie DP, Hollenberg MD et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 2011; 130: 248-282.
137. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR-1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999; 38: 4572-4585.
138. Junge CE, Lee CJ, Hubbard KB, Zhang Z, Olson JJ, Hepler JR et al. Proteaseactivated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol 2004; 188: 94-103.
139. Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, Brat DJ et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci USA 2003; 100: 13019-13024.
140. Wang H, Ubl JJ, Reiser G. Four subtypes of protease-activated receptors, coexpressed in rat astrocytes, evoke different physiological signaling. Glia 2002; 37: 53-63.
141. Striggow F, Riek-Burchardt M, Kiesel A, Schmidt W, Henrich-Noack P, Breder J et al. Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur J Neurosci 2001; 14: 595-608.
142. Greenidge AR, Hall KR, Hambleton IR, Thomas R, Monroe DM, Landis RC. Plasmin activation of glial cells through protease-activated receptor 1. Patholog Res Int 2013; 2013: 314709.
143. Maeda S, Nakajima K, Tohyama Y, Kohsaka S. Characteristic response of astrocytes to plasminogen/plasmin to upregulate transforming growth factor beta 3 (TGFbeta3) production/secretion through proteinase-activated receptor-1 (PAR- 1) and the downstream phosphatidylinositol 3-kinase (PI3K)-Akt/PKB signaling cascade. Brain Res 2009; 1305: 1-13.
144. Tran ND, Correale J, Schreiber SS, Fisher M. Transforming growth factor-beta mediates astrocyte-specific regulation of brain endothelial anticoagulant factors. Stroke 1999; 30: 1671-1678.
145. Mannaioni G, Orr AG, Hamill CE, Yuan H, Pedone KH, McCoy KL et al. Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem 2008; 283: 20600-20611.
146. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, Van Rooijen N et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 2005; 25: 593-606.
147. Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J Cereb Blood Flow Metab 2006; 26: 797-810.
148. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci 2003; 116: 4615-4628.
149. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV. Protein kinase Calpha- RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem 2006; 281: 8379-8388.
150. Sheehan JJ, Zhou C, Gravanis I, Rogove AD, Wu YP, Bogenhagen DF et al. Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. J Neurosci 2007; 27: 1738-1745.
151. Yao Y, Tsirka SE. The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem 2010; 285: 31509-31516.
152. Niego B, Medcalf RL. Improved method for the preparation of a human cellbased, contact model of the blood-brain barrier. J Vis Exp 2013; 12: 81.
153. Reijerkerk A, Kooij G, van der Pol SMA, Leyen T, van het Hof B, Couraud P-O et al. Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier. J Immunol 2008; 181: 3567-3574.